Maria Val-Casals
YOU?
Author Swipe
View article: Supplementary Table 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Quantification of stool metabolites in multiple myeloma patients from the first cohort, measured by nuclear magnetic resonance (NMR) on the day of apheresis, lymphodepletion or 12 monts post CAR-T cell infusion. Apheresis Sample ID Acetate…
View article: Supplementary Table 5 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 5 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Linear regression analysis identifying independent predictors of CD4+ central memory level
View article: Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
upplementary Figure S10 provides a phenotypic characterization of in vitro expanded CAR T-cells that were supplemented with succinate. This includes an analysis of CD4+ naive and terminally differentiated effector T cells, as well as CD4+ …
View article: Supplementary Table 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Main characteristics of the patients, response and safety
View article: Supplementary Table 15 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 15 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Relative quantification of succinic acid in serum of MM patients from the first cohort at apheresis day, using the targeted UHPLC-MS methodology. UHPLC-MS: Ultra High-Performance Liquid Chromatography Mass Spectrometry
View article: Supplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Relative quantification of inosine in serum of MM patients from the first cohort at different time points, using the targeted UHPLC-MS methodology. V1: Apheresis day, V11: 28 days post CAR-T infusion, 12M: 12 months post CAR-T infusion, UH…
View article: Supplementary Table 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Distribution of patients that donated at least one stool sample to the study in cohort 1 and were treated.
View article: Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with th…
View article: Supplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
SCFA evaluation in serum of MM patients from the first cohort at the apheresis day, using gas chromatography-mass spectrometry methodology
View article: Supplementary Figure 24 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 24 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S24 shows the association between alpha diversity and clinical outcomes, specifically presenting Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS). These curves compare patients with hig…
View article: Supplementary Figure 23 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 23 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S23 shows a network of correlations between gut microbial families (green nodes) and metabolites (yellow nodes) associated with clinical response improvement. Green lines denote positive correlations, while red lines i…
View article: Supplementary Figure 4 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 4 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S4 illustrates the pre and post-CAR T-cell infusion systemic short-chain fatty acid profiles in multiple myeloma patients, specifically detailing levels of acetate, propionate, butyrate, isobutyrate, and formate.
View article: Supplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S18 presents LDA scores that indicate differences in taxonomic abundance based on toxicity profiles in multiple myeloma (MM) patients. The figure shows comparisons between patients with and without cytokine release syn…
View article: Supplementary Table 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Metabolite enrichment analysis using metabolites identified in the combined model. Statistical significance was assessed using the false discovery rate (FDR).
View article: Supplementary Table 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
The potential impact of antibiotic usage on gut microbiota 1st cohort.
View article: Supplementary Figure 17 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 17 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S17 highlights statistically significant differences in fecal metabolite abundance between multiple myeloma patients and healthy donors. This figure presents mean fecal metabolite abundance ±SD for various metabolites,…
View article: Supplementary Table 12 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 12 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Quantification of stool metabolites in multiple myeloma patients from the second cohort, measured by nuclear magnetic resonance (NMR) on the day of apheresis.
View article: Supplementary Figure 19 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 19 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S19 illustrates the serum inosine levels in multiple myeloma (MM) patients from the first cohort. This figure tracks the longitudinal changes in inosine levels at apheresis, 28 days post-CAR T-cell infusion, and 12 mon…
View article: Supplementary Table 9 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 9 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Distribution of the second cohort of MM patients that donated stool samples at the apheresis day and were treated.
View article: Supplementary Figure 7 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 7 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S7 illustrates the linear association between serum succinate levels and CAR T-cell phenotypes at apheresis in the first cohort, specifically showing relationships with the CD4+ T-cell memory compartment and the CD8+ T…
View article: Supplementary Figure 12 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 12 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S12 outlines the flow cytometry strategy used for T-cell persistence analysis. This figure includes representative flow cytometry plots of human CD45 expression in mouse blood samples from tumor-bearing mice, detailing…
View article: Supplementary Figure 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S11 demonstrates the in vivo effects of a FOS-diet on CAR T cells using an ARP-1 mouse model. This figure presents a schematic of the experimental setup, analyzes absolute peripheral blood CD4+ and CD8+ T-cell counts a…
View article: Supplementary Figure 22 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 22 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S22 illustrates the association between post-infusion systemic short-chain fatty acid (SCFA) levels and treatment response in multiple myeloma (MM) patients. This figure analyzes serum SCFA levels at both 100 and 180 d…
View article: Supplementary Table 14 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 14 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
SCFA evaluation in serum of MM patients from the first cohort 28-day post CAR-T cell infusion, using gas chromatography-mass spectrometry methodology.
View article: Supplementary Figure 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S8 illustrates the linear association between serum and stool succinate levels at the time of apheresis in multiple myeloma patients.
View article: Supplementary Figure 21 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 21 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S21 shows the association between baseline (apheresis day) systemic short-chain fatty acid levels and treatment response in multiple myeloma patients. This figure analyzes serum SCFA levels at 100 and 180 days post–CAR…
View article: Supplementary Figure 9 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 9 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S9 characterizes the taxa and metabolites associated with T-cell exhaustion markers in the final CAR T-cell product from multiple myeloma patients. This figure specifically shows associations with both CD4+ T cells and…
View article: Supplementary Figure 14 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 14 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure S14 examines the pre-CAR T-cell infusion gut microbiota taxonomic profiles based on the patients' hospital of origin. This figure includes a principal component analysis (PCA) plot showing gut microbiota composition by…
View article: Supplementary Figure 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Supplementary Figure 16. Comparison of gut microbiome profiles in MM patients from the first cohort at baseline (apheresis day) and 12 months post–CAR-T-cell infusion. (A) Principal coordinates analysis (PCA) of bacterial community composi…
View article: Supplementary Table 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Table 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma Open
Parameters used for the clinical data-based model.